Rituximab ® provides high response rates and effective disease palliation in patients with splenic marginal zone lymphoma (SMZL). We conducted a phase II trial in patients with SMZL who were either untreated or were splenectomized but had shown disease progression within 1 year after splenectomy. Treatment consisted of six courses of Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone (R-COMP). Fifty-one patients were eligible for the analysis. The overall response rate was 84%. The 6-year progression-free survival and overall survival were 54% and 72%, respectively. Toxicity was substantial (grade ≥ 3 neutropenia: 26%; grade ≥ 3 infections: 8%). Of the 15 deaths, two occurred on treatment (one sepsis and one pneumonia). Six deaths were due to lymphoma progression, four to secondary neoplasia, one to sepsis, one to pneumonia and one to splenectomy complications. R-COMP should be restricted to patients with bulky disease associated with symptoms or to patients with possible histological transformation.

Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study / Iannitto, E.; Luminari, S.; Tripodo, C.; Mancuso, S.; Cesaretti, M.; Marcheselli, L.; Merli, F.; Stelitano, C.; Carella, A. M.; Fragasso, A.; Montechiarello, E.; Ricciuti, G.; Pulsoni, A.; Paulli, M.; Franco, V.; Federico, M.. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - 56:12(2015), pp. 3281-3287. [10.3109/10428194.2015.1029925]

Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study

Pulsoni A.;
2015

Abstract

Rituximab ® provides high response rates and effective disease palliation in patients with splenic marginal zone lymphoma (SMZL). We conducted a phase II trial in patients with SMZL who were either untreated or were splenectomized but had shown disease progression within 1 year after splenectomy. Treatment consisted of six courses of Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone (R-COMP). Fifty-one patients were eligible for the analysis. The overall response rate was 84%. The 6-year progression-free survival and overall survival were 54% and 72%, respectively. Toxicity was substantial (grade ≥ 3 neutropenia: 26%; grade ≥ 3 infections: 8%). Of the 15 deaths, two occurred on treatment (one sepsis and one pneumonia). Six deaths were due to lymphoma progression, four to secondary neoplasia, one to sepsis, one to pneumonia and one to splenectomy complications. R-COMP should be restricted to patients with bulky disease associated with symptoms or to patients with possible histological transformation.
2015
first line; rituximab; splenic marginal zone lymphoma
01 Pubblicazione su rivista::01a Articolo in rivista
Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study / Iannitto, E.; Luminari, S.; Tripodo, C.; Mancuso, S.; Cesaretti, M.; Marcheselli, L.; Merli, F.; Stelitano, C.; Carella, A. M.; Fragasso, A.; Montechiarello, E.; Ricciuti, G.; Pulsoni, A.; Paulli, M.; Franco, V.; Federico, M.. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - 56:12(2015), pp. 3281-3287. [10.3109/10428194.2015.1029925]
File allegati a questo prodotto
File Dimensione Formato  
Iannitto_Rituximab_2015.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 552.4 kB
Formato Adobe PDF
552.4 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1349275
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 21
  • ???jsp.display-item.citation.isi??? 18
social impact